Effectiveness and Safety of Avatrombopag in Liver Cancer Patients with Severe Thrombocytopenia: Real-World Data and Challenges

Figure 2

Thrombopoietic effect of avatrombopag in liver cancer patients with and without CLD. (a) Scatter plot of peak platelet count in the CLD and non-CLD groups after avatrombopag treatment; (b) scatter plot of absolute platelet increase in the CLD and non-CLD groups after avatrombopag treatment; (c) percentages of responders after avatrombopag treatment in the CLD and non-CLD groups; (d) percentages of patients whose absolute platelet increased ≥20×109/L after avatrombopag treatment in the CLD and non-CLD groups; (e) percentages of patients who had peak platelet count ≥50×109/L after avatrombopag treatment in the CLD and non-CLD groups; (f) scatter plot of baseline platelet count of patients with peak platelet count ≥50 × 109/L or <50 × 109/L after avatrombopag treatment in CLD group. CLD: chronic liver disease.

(a)

(b)

(c)

(d)

(e)

(f)